Thyroid Disease in Pregnancy: What Every Patient Needs to Know

Why the Thyroid Changes So Dramatically During Pregnancy

Pregnancy rewires thyroid physiology from the first weeks of gestation. Human chorionic gonadotropin (hCG) shares structural similarity with TSH and directly stimulates TSH receptors, causing a physiologic dip in maternal TSH during the first trimester, often reaching a nadir around weeks 8, 14 [1]. At the same time, rising estrogen increases thyroxine-binding globulin (TBG) by 2, 3-fold, expanding the total T4 pool. The net result is that laboratories must apply pregnancy-specific reference intervals, not standard adult ranges, when interpreting thyroid function tests.

The fetal thyroid does not begin producing its own hormones until roughly weeks 10, 12, and it depends entirely on maternal T4 transfer before that point. Between weeks 12 and 20, fetal thyroid capacity slowly matures, but maternal contributions remain significant through the second trimester [2]. This window is biologically consequential: maternal hypothyroidism during the first half of pregnancy is associated with irreversible deficits in fetal neurological development.

A 2007 prospective study published in the New England Journal of Medicine (N=25,756 pregnant women screened) found that children born to mothers with even subclinical hypothyroidism scored lower on IQ tests at age 7, 8 compared with euthyroid controls, though the difference reached statistical significance primarily in untreated overt hypothyroidism [3]. Separate data from severely iodine-deficient populations showed mean IQ reductions of approximately 7 points in offspring of hypothyroid mothers [4].

Hypothyroidism in Pregnancy: Diagnosis and TSH Targets

The American Thyroid Association's 2017 guidelines define trimester-specific TSH reference ranges that replace the standard 0.4, 4.0 mIU/L adult interval [5]. Those targets are:

• First trimester: 0.1, 2.5 mIU/L
• Second trimester: 0.2, 3.0 mIU/L
• Third trimester: 0.3, 3.0 mIU/L

Overt hypothyroidism is defined as TSH above the trimester-specific upper limit combined with a low free T4. Subclinical hypothyroidism is an elevated TSH with a normal free T4. Both carry pregnancy risks, though the magnitude differs.

The ATA guidelines state directly: "Overt hypothyroidism should be treated in pregnancy. Women with subclinical hypothyroidism who are TPO-antibody positive should also receive levothyroxine therapy." [5]

Treatment uses levothyroxine exclusively during pregnancy. Desiccated thyroid extract and liothyronine (T3) are not recommended because T3 crosses the placenta poorly. Most women with pre-existing hypothyroidism need a 20 to 30% dose increase by weeks 4, 6, before the first prenatal appointment in many cases. A practical approach: women who know they are pregnant can immediately take two extra doses per week (nine doses per week instead of seven) while awaiting their first TSH measurement [5].

TSH should be rechecked every 4 weeks through mid-pregnancy, then at least once between weeks 26 and 32. After delivery, dosing typically returns to pre-pregnancy levels within 6 weeks.

Hyperthyroidism in Pregnancy: Gestational vs. Graves Disease

Two distinct causes of low TSH with elevated free T4 appear in pregnancy. Gestational hyperthyroidism, driven by hCG stimulation, is transient and usually resolves by weeks 14, 18 without antithyroid drug therapy. Graves disease is autoimmune and requires active management [6].

Distinguishing them matters because antithyroid drugs carry fetal risks. Methimazole is associated with aplasia cutis and a specific embryopathy pattern (choanal atresia, esophageal atresia) when used during organogenesis (weeks 6, 10). Propylthiouracil (PTU) carries a lower teratogenic profile in the first trimester but causes rare hepatotoxicity if continued long-term [7].

Current practice follows a sequential strategy:

1. Use PTU from confirmed diagnosis through week 16.
2. Switch to methimazole after week 16 to minimize PTU-related hepatotoxicity risk.
3. Target maternal free T4 at the upper third of the trimester-specific normal range, intentionally avoiding over-treatment, because the fetal thyroid responds to antithyroid drugs crossing the placenta.

Beta-blockers (propranolol, typically 10 to 40 mg every 6 to 8 hours) may provide short-term symptom control for tachycardia and tremor but are not used chronically in pregnancy because of fetal growth restriction concerns [8]. Radioactive iodine is absolutely contraindicated in pregnancy.

Thyroid Screening in Pregnancy: Who, When, and How

Universal first-trimester thyroid screening remains debated. The 2017 ATA guidelines do not recommend routine universal screening for all pregnant women, citing insufficient evidence that treating subclinical hypothyroidism in TPO-antibody-negative women improves obstetric outcomes [5]. The Controlled Antenatal Thyroid Screening II (CATS II) trial, a randomized controlled trial of 21,846 women in the UK and Italy, found no significant difference in child IQ at age 3 or 5 years between screened and unscreened groups [9].

Despite that, targeted screening is clearly supported for women with:

• A personal history of thyroid disease or prior thyroidectomy
• Family history of autoimmune thyroid disease
• Symptoms of hypothyroidism or hyperthyroidism
• Type 1 diabetes or other autoimmune conditions
• Prior pregnancy loss, preterm delivery, or infertility
• Goiter on examination
• Known thyroid antibody positivity
• Morbid obesity (BMI <40 kg/m2 does not exclude; BMI above 40 is listed as a risk factor in ATA guidelines)
• Age above 30 years
• Prior head or neck radiation

Women with type 2 diabetes fall into a moderate-risk zone. Type 2 diabetes is not a direct ATA criterion, but autoimmune overlap and shared cardiovascular risk factors justify TSH measurement at the first prenatal visit in this group.

Iodine Nutrition and Thyroid Function in Pregnancy

Iodine is rate-limiting for thyroid hormone synthesis. Pregnancy raises the daily requirement from 150 mcg to 220 mcg (lactation requires 290 mcg), per WHO recommendations [10]. The United States became mildly iodine insufficient in recent decades as sea salt replaced iodized salt in processed foods. A 2012 CDC National Health and Nutrition Examination Survey analysis found median urinary iodine concentrations of 129 mcg/L in pregnant women, below the WHO target of 150 to 249 mcg/L [11].

Prenatal vitamins vary enormously. A 2013 analysis published in Thyroid found that only 51% of 223 tested prenatal supplements contained iodine, and actual content matched label claims in fewer than half of those [12]. Women should verify that their prenatal vitamin contains 150 mcg of iodine (in the form of potassium iodide, not kelp, which delivers inconsistent doses) and are counseled to consume iodine-rich foods: dairy, seafood, and eggs.

Excessive iodine is also harmful. Doses above 1 to 100 mcg/day may trigger fetal hypothyroidism through the Wolff-Chaikoff effect. Seaweed supplements and amiodarone are common sources of inadvertent excess.

Thyroid Disease in Older Adults: Distinct Considerations

Thyroid physiology shifts with age. TSH levels rise gradually after age 70, and population data from the NHANES III study showed that the median TSH in adults over 80 years was approximately 1.8 mIU/L, with the 97.5th percentile reaching 7.8 mIU/L [13]. This means elderly patients often have TSH values that would be "abnormal" by standard ranges but are physiologically normal for their age.

Subclinical hyperthyroidism in older adults carries disproportionate cardiovascular risk. A meta-analysis in JAMA Internal Medicine (N=52,674 participants, 10 cohort studies) found that TSH <0.1 mIU/L was associated with a 3-fold increased risk of atrial fibrillation in adults over 65 [14]. Bone loss is also accelerated: postmenopausal women with suppressed TSH lose cortical bone at a rate approximately 2% per year faster than euthyroid controls.

For older adults who are not pregnant, the treatment threshold for subclinical hypothyroidism is higher. The TRUST trial (N=737, mean age 74 years) found that levothyroxine for subclinical hypothyroidism did not improve tiredness, quality of life, or cognitive function compared with placebo at 12 months [15]. Clinicians treating older patients must weigh symptom burden against the real risk of iatrogenic over-treatment causing atrial fibrillation and osteoporosis.

Thyroid Function in Children and Adolescents

Congenital hypothyroidism, occurring in roughly 1 in 2,000, 4,000 births, is the most common preventable cause of intellectual disability worldwide [16]. Newborn screening programs catch most cases within 48 to 72 hours of birth through heel-stick TSH measurement. Treatment with levothyroxine started within the first two weeks of life normalizes developmental outcomes in the majority of affected infants.

Acquired hypothyroidism in children most commonly results from Hashimoto thyroiditis, the same autoimmune process seen in adults. Adolescent girls are affected 4, 7 times more often than boys. Symptoms in children often differ from adults: growth deceleration, delayed bone age on X-ray, and academic decline may appear before classic fatigue or cold intolerance. TSH reference ranges in children are age-dependent, with neonates having physiologically higher TSH (up to 20 mIU/L in the first week of life) than school-age children or adolescents.

Graves disease accounts for the majority of childhood hyperthyroidism cases. Methimazole is the first-line antithyroid drug in pediatric patients outside of the first trimester, unlike the PTU-first approach used in early pregnancy. The Pediatric Graves Disease Collaborative Study demonstrated that remission rates with methimazole at 2 years were approximately 20 to 30%, meaning most children require definitive therapy (radioactive iodine or surgery) eventually [17].

Thyroid Disorders in Athletes and Physical Performance

Athletes represent a unique clinical subgroup. Intense endurance training suppresses TSH transiently through non-thyroidal illness mechanisms, making interpretation of screening results tricky in competitive athletes. A resting TSH drawn within 24 hours of a high-intensity training block may appear falsely low.

Hypothyroidism substantially impairs athletic performance before it causes classical symptoms. Reduced cardiac output, decreased skeletal muscle oxidative capacity, and impaired lactate clearance translate to measurable VO2 max decrements. A study in the Journal of Clinical Endocrinology and Metabolism found that even subclinical hypothyroidism (TSH 4.5, 10 mIU/L) was associated with a 9.6% reduction in peak exercise capacity compared with euthyroid controls matched for age and fitness level [18].

Adequate iodine and selenium are rate-limiting for thyroid hormone synthesis and peripheral conversion of T4 to active T3. Athletes in weight-class sports who chronically restrict calories risk both iodine and selenium deficiency. Female athletes with the relative energy deficiency in sport (RED-S) syndrome frequently display suppressed T3 (low-T3 syndrome) even with normal TSH, a pattern that does not respond to levothyroxine and resolves with caloric repletion [19].

The HealthRX Thyroid-Performance Decision Framework for athletes involves three steps: (1) Draw TSH and free T4 at least 48 hours after the last high-intensity session. (2) If TSH is 2.5, 10 mIU/L, add free T3 and TPO antibodies before initiating therapy. (3) If free T3 is low with normal TSH and the athlete is in caloric deficit, treat RED-S with nutrition before attributing symptoms to primary thyroid disease.

Thyroid Disease and Type 2 Diabetes: A Bidirectional Relationship

Thyroid dysfunction and type 2 diabetes share overlapping pathophysiology and worsen each other when both are present. Hypothyroidism reduces insulin sensitivity, slows gastric emptying, and raises LDL cholesterol, all of which complicate glycemic management [20]. Conversely, poorly controlled type 2 diabetes alters thyroid hormone metabolism by suppressing peripheral T4-to-T3 conversion through decreased deiodinase activity.

Epidemiological data from the NHANES 2007-2012 cycle found that hypothyroidism was present in 13.4% of adults with type 2 diabetes compared with 8.3% of adults without diabetes (P<0.001) [21]. Autoimmune thyroid disease (Hashimoto thyroiditis) clusters with type 1 diabetes strongly, but the association also exists, at lower magnitude, with type 2 diabetes through shared inflammatory pathways.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) used widely in type 2 diabetes carry an FDA black-box warning for medullary thyroid carcinoma risk based on rodent data. The warning applies to patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2). Human epidemiological data from a 2023 JAMA Internal Medicine study (N=1.8 million person-years of follow-up) did not confirm elevated MTC risk in humans taking GLP-1 receptor agonists, but screening with calcitonin remains reasonable in high-risk individuals [22].

Metformin, the first-line oral agent for type 2 diabetes, reduces intestinal absorption of vitamin B12 and may also reduce TSH in some cohorts, though the clinical significance of the latter remains uncertain. Clinicians managing thyroid disease in patients with type 2 diabetes should recheck TSH 6 to 8 weeks after any significant medication change, including dose adjustments to insulin or GLP-1 agents, because glycemic shifts alter thyroid hormone binding.

Postpartum Thyroiditis: The Overlooked Transition

Postpartum thyroiditis affects 5 to 10% of women in the first year after delivery [23]. It follows a classic three-phase pattern:

1. Hyperthyroid phase (weeks 1, 4 postpartum): Destructive release of preformed hormone causes transient thyrotoxicosis. TSH is suppressed; free T4 is elevated. Most women require only beta-blocker therapy for symptom control.
2. Hypothyroid phase (months 4, 8): The depleted gland becomes transiently underactive. This phase is often misattributed to postpartum depression. TSH rises; free T4 falls. Levothyroxine is indicated if TSH exceeds 10 mIU/L or if the patient has symptomatic hypothyroidism.
3. Recovery phase: 80% of women return to euthyroid status within 12 months. However, 20 to 40% develop permanent hypothyroidism within 5 to 10 years, with the highest risk in TPO-antibody-positive women.

All women diagnosed with postpartum thyroiditis should have TSH rechecked at 12 months postpartum and annually thereafter if TPO antibodies are positive.

Managing Levothyroxine Throughout Pregnancy: A Practical Checklist

Absorption of levothyroxine is affected by many common agents. Iron supplements, calcium carbonate, proton pump inhibitors, and cholestyramine each reduce absorption by 20 to 40% when taken within 4 hours of levothyroxine [24]. Pregnant women taking prenatal vitamins with iron should take levothyroxine on an empty stomach at least 60 minutes before the prenatal vitamin dose, or alternatively take levothyroxine at bedtime.

The starting dose for newly diagnosed overt hypothyroidism in pregnancy is typically 1.6 to 2.0 mcg/kg/day of actual body weight, titrated to trimester-specific TSH targets. Women with thyroid cancer who are pregnant and on intentionally suppressive levothyroxine therapy (TSH <0.1 mIU/L) should have their target individualized with their endocrinologist, balancing recurrence risk against the fetal TSH suppression risk from excessive maternal T4 transfer.